微芯生物：西奥罗尼胶囊获临床试验批准

Group 1 - The core point of the article is that Microchip Biotech has received approval from the National Medical Products Administration for clinical trials of its product, Xioroni capsules, which are intended for the treatment of metastatic pancreatic ductal adenocarcinoma in combination with PD-1 monoclonal antibodies and chemotherapy [1] Group 2 - Xioroni capsules are a novel small molecule anti-tumor drug developed by the company, featuring a new chemical structure and a multi-pathway anti-tumor mechanism [1]